Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early oral isotretinoin versus standard of care in moderate acne in skin of color
2023-507519-36-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acne vulgaris and Post-inflammatory hyperpigmentation (PIH) comparing Early oral isotretinoin with Standard of care (2 arms). Primary endpoint: Primary ARP severity outcome at 6 months. Planned start Mar 2024; status: authorised.
02
Drugs
isotretinoin
03
Conditions
acne vulgarisPost-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on 2023-507519-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507519-36-00.